Literature DB >> 7461023

Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment.

K O Haustein.   

Abstract

Patients suffering from congestive heart failure received maintenance doses of digitoxin (N = 10) or digoxin (N = 8). The plasma glycoside concentration was determined, and after a single dose of 3H-digitoxin or 3H-digoxin, the decline and excretion of radioactivity were measured over a period of 7 (digitoxin) and 3 days (digoxin). Plasma radioactivity declined with a T1/2 beta between 77 and 234 h (mean 138 h) in the case of digitoxin and with a T1/2 beta between 9.2 and 38.6 h (mean 23.5 h) for digoxin. A close correlation between T1/2 beta and excreted radioactivity and T1/2 beta and total plasma level was found for digitoxin. In 4 patients TLC of urine showed that interindividual variations in digitoxin elimination could possibly be attributed to variation in metabolism, resulting in the production of different metabolites. Predicted digitoxin plasma levels agreed well with measured values. The maintenance dose could be calculated from the total body clearance (VCl) and a presumed plasma glycoside level. The recommended technique facilitates dosage calculations in patients treated with digitoxin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7461023     DOI: 10.1007/bf00558383

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  [The bis- and mono-digitoxosides of digitoxigenin and digoxigenin: metabolites of digitoxin].

Authors:  K REPKE
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1959

2.  Metabolic fate of radioactive digitoxin in human subjects.

Authors:  G T OKITA; P J TALSO; J H CURRY; F D SMITH; E M GEILING
Journal:  J Pharmacol Exp Ther       Date:  1955-12       Impact factor: 4.030

3.  Studies on digitalis. VII. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites.

Authors:  L Storstein
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

Review 4.  Factors causing interindividual variations of drug concentrations in blood.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

5.  Digitoxin studies. Serum concentration during digitalization, maintenance therapy and withdrawal. Estimation of proper maintenance dose.

Authors:  K Gjerdrum
Journal:  Acta Med Scand       Date:  1972 Jan-Feb

6.  Interactions between digitoxin and other drugs in vitro and in vivo.

Authors:  H M Solomon; S Reich; N Spirt; W B Abrams
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

7.  Fate of orally administered 3H-digitoxin in man with special reference to the absorption.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Circulation       Date:  1971-06       Impact factor: 29.690

8.  An improved method for measuring plasma and tissue concentrations of digitalis glycosides.

Authors:  J M Lowenstein; E M Corrill
Journal:  J Lab Clin Med       Date:  1966-06

9.  The measurement of digitoxin in human serum by radioimmunoassay.

Authors:  G C Oliver; B M Parker; D L Brasfield; C W Parker
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

10.  Individualization of drug dosage during long-term treatment with phenprocoumon (Falithrom).

Authors:  K O Haustein; M Richter; G Vogel; E Mittag
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-08
View more
  1 in total

1.  Digitoxin accumulation.

Authors:  H R Ochs; J Pabst; D J Greenblatt; J Hartlapp
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.